The mTOR gene in humans produces the protein known as mTOR (mammalian target of rapamycin). A serine/threonine protein kinase called mTOR controls transcription, protein synthesis, cell motility, growth, and proliferation in living things. The phosphatidylinositol 3-kinase-related kinase protein family includes mTOR. Growth factors and amino acids are just two examples of the input from upstream pathways that mTOR integrates.Additionally, mTOR detects cellular energy, oxygen, and nutrient levels. In human diseases like diabetes, obesity, depression, and some cancers, the mTOR pathway is dysregulated. By collaborating with its intracellular receptor FKBP12, rapamycin inhibits mTOR. The mTOR FKBP12-Rapamycin Binding (FRB) domain is directly contacted by the FKBP12-rapamycin complex, which inhibits mTOR activity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0183 | Tacrolimus (FK-506, Fujimycin, FR900506, Prograf) | 104987-11-3 | Tacrolimus(FK506, Fujimycin, FR-900506, Prograf),a natural macrocyclic lactone isolated from the fungus Streptomyces tsukubaensis, is a potent immunosuppressive agentused with other medications to prevent rejection of organ (kidney, heart, liver) transplant. |
|
V0178 | Temsirolimus (CCI779, NSC683864) | 162635-04-3 | Temsirolimus (also known as CCI-779, NSC-683864; Torisel), an ester analog of rapamycin, is a potent and specific inhibitor ofmTOR (mammalian target of rapamycin) with potential anticancer activity. |
|
V70251 | Thioether-cyclized helix B peptide, CHBP | 1453840-35-1 | Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renal protection by inhibiting mTORC1 and activating mTORC2-induced autophagy. |
|
V81576 | Thioether-cyclized helix B peptide, CHBP TFA | Thioether-cyclized helix B peptide, CHBP (TFA) is the TFA form of Thioether-cyclized helix B peptide, CHBP. | |
|
V70229 | TMBIM6 antagonist-1 | 123134-61-2 | TMBIM6 antagonist-1 is a potential TMBIM6 antagonist that can inhibit/disrupts the binding of TMBIM6 to mTORC2, reduces mTORC2 activity, and regulates TMBIM6 to release Ca2+. |
|
V0187 | Torin 1 | 1222998-36-8 | Torin 1, a tricyclic benzonaphthyridinone analog, is a novel, potent and selective mTORC1/2 (mammalian target of rapamycin complex1/2) inhibitor with potential anticancer activity. |
|
V0176 | Torkinib (PP242) | 1092351-67-1 | Torkinib (also known as PP242) is a novel, potent and selective ATP-competitive mTOR (mammalian target of rapamycin) inhibitorwith potential anticancer activity. |
|
V0195 | Vistusertib (AZD2014) | 1009298-59-2 | Vistusertib (formerly AZD-2014) is a novel, potent, orally bioavailable and ATP competitiveinhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity. |
|
V0203 | WAY-600 | 1062159-35-6 | WAY-600 (WAY600) is a novel, potent, ATP-competitive and selective inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity. |
|
V0193 | WYE-354 | 1062169-56-5 | WYE-354 (WYE 354) is a novel, potent, specific, cell-permeable and ATP-competitive mTOR (mammalian target of rapamycin) inhibitor with potential anticancer/antitumor activity. |
|
V0201 | WYE-687 | 1062161-90-3 | WYE-687 is a novel, potent, ATP-competitive and selective inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity. |
|
V69193 | WYE-687 dihydrochloride | 1702364-87-1 | WYE-687 di-HCl is an ATP-competitive mTOR inhibitor (antagonist) with IC50 of 7 nM. |
|
V0197 | WYE125132 (WYE132) | 1144068-46-1 | WYE-125132 (also known as WYE 132) is a novel, highly potent, selective and ATP-competitive inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity. |
|
V0206 | XL388 | 1251156-08-7 | XL388 is a novel, highly potent, selective, oral, ATP-competitive inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity. |
|
V70241 | Zederone (zedoary epoxy ketone) | 7727-79-9 | Zederone is a germacrane-type sesquiterpene with potent cytotoxic effect against human leukocyte cancer cells and human prostate cancer cells. |
|
V0208 | Zotarolimus (ABT578; A-179578) | 221877-54-9 | Zotarolimus (also known as ABT-578; A 179578), atetrazole-based and semi-synthetic analog of rapamycin, is ahighly potentimmunosuppressant with the potential to be used for preventing coronary artery restenosis. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
